Sino Biopharmaceutical Limited
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a SBMFF research report →
Price Chart
About the company
Sino Biopharmaceutical Limited operates as a leading investment holding entity and a research and development-focused pharmaceutical conglomerate, primarily active within the People's Republic of China. Its business activities are organized into three primary divisions: Modernised Chinese Medicines and Chemical Medicines, Investment initiatives, and other miscellaneous operations. The company offers a comprehensive range of pharmaceutical products spanning various therapeutic areas.
- CEO
- S. Y. Tse
- IPO
- 2010
- Employees
- 21,435
- HQ
- Hong Kong, HK
Get TickerSpark's AI analysis on SBMFF
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $11.60B
- P/E
- 35.90
- Fwd P/E
- 2.64
- PEG
- 1.20
- P/S
- 2.62
- P/B
- 2.74
- EV/EBITDA
- 12.67
- Div Yield
- 1.83%
- Gross Margin
- 82.07%
- Op Margin
- 21.84%
- Net Margin
- 7.36%
- ROE
- 7.32%
- ROIC
- 8.99%
Latest fiscal year · YoY change
- Revenue
- $31.01B+7.4%
- Gross Profit
- $25.45B+8.2%
- Op Income
- $6.64B
- Net Income
- $2.28B-34.8%
- EPS
- $0.13-35.0%
- OCF Growth
- +40.5%
- FCF Growth
- +34.2%
- 52W High
- $1.24
- 52W Low
- $0.59
- 50D MA
- $0.62
- 200D MA
- $0.76
- Beta
- 0.60
- RSI (14)
- 70
- Avg Volume
- 222
No earnings-call transcripts are available for SBMFF yet.
- Free Float
- 51.2%
- Shares Outstanding
- 17.81B
- Float Shares
- 9.12B
Held by 2 ETFs
Biggest fund positions in SBMFF by dollar value.
Our SBMFF coverage
Recent articles, reports, and earnings notes.
No research on SBMFF yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate SBMFF report →Sino Biopharmaceutical, GSK expand alliance with China rights to respiratory drugs
reuters.com · Jul 8
AstraZeneca, Sino Biopharm Sign Up to $1.9 Billion Respiratory Drug Licensing Deal
wsj.com · Jul 7
Hong Kong-listed Sino Biopharma, AstraZeneca sign respiratory drug deal worth up to $1.9 billion
reuters.com · Jul 7
Sino Biopharmaceutical to divest 67% stake in unit CP Qingdao for $253 mln
reuters.com · Feb 6
Chinese Company Gets FDA Approval For Drug To Fight Chemotherapy Nausea
forbes.com · Mar 7
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.